Changes in Hong Kong stocks | Federal Pharmaceuticals (03933) rose more than 6% in the first half of the year, profit attributable to shareholders increased 27% year-on-year, and various products in the pharmaceutical products sector made key progress

The Zhitong Finance App learned that Federal Pharmaceuticals (03933) rose more than 6%. As of press release, it had risen 4.56% to HK$17.19, with a turnover of HK$180 million.

According to the news, recently, Federal Pharmaceuticals announced the results for the first half of 2025. According to CICC, 25H1's revenue was 7.519 billion yuan, +4.8% year on year; gross profit was 3,924 billion yuan, corresponding gross profit margin of 52.2%, +5.6ppt year on year; profit before tax was 2,420 billion yuan, +27.24% year on year; and realized net profit of 1,894 billion yuan, +27.02% year over year. The increase was mainly due to Novo Nordisk's one-time contribution to UBT251 licensing fees and insulin series dosage, which is in line with this forecast.

According to a research report released by Open Source Securities, the company's research project is progressing smoothly, and various products have made key progress in the formulation product sector, including approval for the listing of liraglutide injections, approval for polyvinyl alcohol eye drops, acceptance of the marketing application for simeglutide injections, and acceptance of injectable ceftriaxone sodium through generic drug consistency evaluation. A UBT251 licensing agreement was reached with Novo Nordisk to further improve the layout of innovative drug cooperation.